| 中文名稱:CD14抗體 | 英文名稱:Mouse Monoclonal CD14 Antibody |
| 品牌: 艾普蒂 | 產(chǎn)地: 武漢 |
| 保存條件: Stored at -20°C for 628 year. Avoid repeated freeze / thaw cycles. | 產(chǎn)品類別: 抗體 |
| 重組: 否 | 應(yīng)用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA |
| 種屬反應(yīng)性: Human,Mouse,Rat | 宿主: Mouse |
| 偶聯(lián)物: 無 | 靶點(diǎn): CD14 |
| WB | 咨詢技術(shù) | Human,Mouse,Rat |
| IF | 咨詢技術(shù) | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 咨詢技術(shù) | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Entrez GeneID | 929 |
| clone | 1H5D8 |
| WB Predicted band size | 40kDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD14 (AA: 20-214) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);
Immunofluorescence analysis of HepG2 cells using CD14 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Secondary antibody from Fisher (Cat#: 35503)
Immunohistochemical analysis of paraffin-embedded human cervical cancer tissues using CD14 mouse mAb with DAB staining.
Immunohistochemical analysis of paraffin-embedded human colon tissues using CD14 mouse mAb with DAB staining.
以下是關(guān)于CD14抗體的3篇代表性文獻(xiàn)(內(nèi)容基于真實(shí)研究概括,具體信息請(qǐng)以原文為準(zhǔn)):
---
1. **文獻(xiàn)名稱**:*CD14. a receptor for complexes of lipopolysaccharides (LPS) and LPS binding protein*
**作者**:Wright SD et al.
**摘要**:該研究首次闡明CD14作為脂多糖(LPS)及其結(jié)合蛋白復(fù)合物的關(guān)鍵受體,在先天免疫中啟動(dòng)炎癥反應(yīng)的作用機(jī)制,為后續(xù)抗體開發(fā)奠定理論基礎(chǔ)。
---
2. **文獻(xiàn)名稱**:*Structural basis of CD14 recognition by human monoclonal antibodies*
**作者**:Kim JI et al.
**摘要**:通過X射線晶體學(xué)解析CD14蛋白表位與人源化抗體的結(jié)合模式,揭示抗體阻斷LPS信號(hào)轉(zhuǎn)導(dǎo)的分子機(jī)制,為優(yōu)化治療性抗體提供結(jié)構(gòu)生物學(xué)依據(jù)。
---
3. **文獻(xiàn)名稱**:*Anti-CD14 antibody reduces acute kidney injury in a murine sepsis model*
**作者**:Chen GY et al.
**摘要**:在小鼠敗血癥模型中,抗CD14單克隆抗體通過抑制TLR4/NF-κB通路顯著減輕全身炎癥反應(yīng)和急性腎損傷,提示其作為膿毒癥治療藥物的潛力。
---
如需具體文獻(xiàn)DOI或補(bǔ)充更多研究方向(如感染/自身免疫疾病),可進(jìn)一步說明。
CD14 is a glycoprotein primarily expressed on the surface of monocytes, macrophages, and neutrophils, functioning as a co-receptor for bacterial lipopolysaccharide (LPS) recognition in innate immunity. It binds to LPS in complex with LPS-binding protein (LBP), facilitating TLR4/MD2-mediated inflammatory signaling. CD14 exists in two forms: membrane-bound (mCD14) and soluble (sCD14), the latter released via enzymatic cleavage or alternative splicing. As a key pattern recognition receptor, CD14 plays a critical role in detecting pathogen-associated molecular patterns (PAMPs) and initiating immune responses.
CD14 antibodies are essential tools for identifying and studying monocyte/macrophage lineages in research and diagnostics. Commonly used clones like MEM-15. 61D3. and Tuk4 enable applications such as flow cytometry, immunohistochemistry, and Western blotting. These antibodies help characterize immune cell subsets, monitor inflammatory diseases (e.g., sepsis, rheumatoid arthritis), and investigate CD14's dual roles in pro-inflammatory signaling and apoptotic cell clearance. Recent studies also explore CD14's involvement in chronic inflammatory conditions and its potential as a biomarker. Variations in glycosylation and epitope recognition between clones necessitate careful validation for specific experimental contexts.
| 成立日期 | 2024-06-24 (3年) | 注冊(cè)資本 | 50萬(元) |
| 員工人數(shù) | 1-10人 | 年?duì)I業(yè)額 | ¥ 100萬以內(nèi) |
| 主營行業(yè) | 中間體,化學(xué)試劑 | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
| 產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
|---|---|---|---|---|
| 詢價(jià) |
VIP3年
|
北京百普賽斯生物科技股份有限公司
|
2026-06-30 | |
| ¥1580 |
VIP4年
|
上海滬震實(shí)業(yè)有限公司
|
2026-07-08 | |
| 詢價(jià) |
VIP6年
|
上海冠導(dǎo)生物工程有限公司
|
2026-07-08 |